PHVS News

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology